Document is current
Any future updates will be listed below
-
Authors
Ito, Kenichi https://orcid.org/0000-0001-5882-7631
Kitagawa, Tomoko
Motohashi, Saya
Hirano, Kazuhiko https://orcid.org/0009-0007-8560-1858
Sekiguchi, Naohiro https://orcid.org/0000-0001-9860-8257
- License Information
-
More Information
Article History
Received: 1 September 2025
Revised: 14 October 2025
Accepted: 27 October 2025
First Online: 12 November 2025
Declarations
:
: This study was performed in accordance with the principles of the Declaration of Helsinki and approved by the Institutional Review Board of our hospital (Disaster Medical Center IRB 2022–33).Informed consent was obtained through an opt-out process on the website, and individuals who declined participation were excluded from the analysis.
: Financial Interests: Naohiro Sekiguchi has received honoraria from Janssen, Ono, and BeOne Medicines and research funding from Incyte Biosciences Japan, Janssen, Mitsubishi Tanabe Pharma Corporation, MSD, and Ono.
